The changes in urinary crystal properties in patients with calcium oxalate (CaOx) calculi after oral administration of potassium citrate (K3cit) were investigated via atomic force microscopy (AFM), scanning electron microscopy (SEM), X-ray powder diffractometry (XRD), and zeta potential analyzer. The AFM and SEM results showed that the surface of urinary crystals became concave, the edges and corners of crystals became blunt, the average size of urinary crystallines decreased significantly, and aggregation of urinary crystals was reduced. These changes were attributed to the significant increase in concentration of excreted citrate to ?mg/L after K3cit intake from ?mg/L before K3cit intake. After the amount of urinary citrate was increased, it complexed with Ca2+ ions on urinary crystals, which dissolved these crystals. Thus, the appearance of concave urinary crystals was a direct evidence of CaOx dissolution by citrate in vivo. The XRD results showed that the quantities and species of urinary crystals decreased after K3cit intake. The mechanism of inhibition of formation of CaOx stones by K3cit was possibly due to the complexation of Ca2+ with citrate, increase in urine pH, concentration of urinary inhibitor glycosaminoglycans (GAGs), and the absolute value of zeta potential after K3cit intake. 1. Introduction Nephrolithiasis, characterized by renal calculi, is a disorder that has recently shown a trend of rising incidence around the world. Renal calculi mainly contain calcium oxalate (CaOx) crystals [1]. However, knowledge about its pathogenesis is limited thus far [2, 3], and the high recurrence rate is still an important clinical issue [4]. Although CaOx is supersaturated in urine, the formation of renal calculi in healthy people is difficult because of all kinds of inhibitors in urine, including citrate, magnesium, osteopontin, and tyrosine hydroxylase [5]. Chemically speaking, CaOx calculi formation is closely related to with the following factors: high concentration of calcium and oxalate in urine, nucleation, growth and aggregation of CaOx crystals, and adhesion of calcium oxalate monohydrate (COM) to renal tubular epithelial cells [6]. CaOx calculi formation is thought to follow two main routes, (slow) formation of subepithelial plaques at papillary tips and (rapid) formation of intratubular plugs [7]. Potassium citrate (K3cit) is one of the main drugs for treatment and prevention of renal calculi. In July 1985, the US Food and Drug Administration approved K3cit as a single drug to treat CaOx calculi with low urinary citrate and uric acid
References
[1]
M. Y. M. Fazil and A. Salim, “Clinical risk index in urolithiasis,” Urological Research, vol. 37, no. 5, pp. 283–287, 2009.
[2]
X.-Q. Yao, J.-M. Ouyang, H. Peng, W.-Y. Zhu, and H.-Q. Chen, “Inhibition on calcium oxalate crystallization and repair on injured renal epithelial cells of degraded soybean polysaccharide,” Carbohydrate Polymers, vol. 90, no. 1, pp. 392–398, 2012.
[3]
S. Zhang, Z.-X. Su, X.-Q. Yao, H. Peng, S.-P. Deng, and J.-M. Ouyang, “Mediation of calcium oxalate crystal growth on human kidney epithelial cells with different degrees of injury,” Materials Science and Engineering C, vol. 32, no. 4, pp. 840–847, 2012.
[4]
Z. Jing, G. Z. Wang, J. Ning, J. W. Yang, G. Yan, and Y. Fang, “Analysis of urinary calculi composition by infrared spectroscopy: a prospective study of 625 patients in Eastern China,” Urological Research, vol. 38, no. 2, pp. 111–115, 2010.
[5]
C.-C. Liu, S.-P. Huang, L.-Y. Tsai et al., “The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis,” Clinica Chimica Acta, vol. 411, no. 9-10, pp. 739–743, 2010.
[6]
H. Peng, J.-M. Ouyang, X.-Q. Yao, and R.-E. Yang, “Interaction between sub-micron COD crystals and African green monkey renal epithelial cell,” The International Journal of Nanomedicine, vol. 7, no. 8, pp. 4727–4737, 2012.
[7]
J. C. Williams and J. A. McAter, “Retention and growth of urinary stones: insights from imaging,” Journal of Nephrology, vol. 26, pp. 25–31, 2013.
[8]
H. A. Fuselier, K. Moore, and J. Lindberg, “Agglomeration inhibition reflected stone-forming activity during long-term potassium citrate therapy in calcium stone formers,” Urology, vol. 52, no. 6, pp. 988–994, 1998.
[9]
S. Tarkan, A. Aysegul, and K. Sadettin, “Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis,” Journal of Endourology, vol. 16, no. 3, pp. 149–152, 2002.
[10]
M. Robert, A.-M. Boularan, O. Delbos, J. Guiter, and B. Descomps, “Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects,” Urologia Internationalis, vol. 60, no. 1, pp. 41–46, 1998.
[11]
M. Daudon, C. Hennequin, G. Boujelben, B. Lacour, and P. Jungers, “Serial crystalluria determination and the risk of recurrence in calcium stone formers,” Kidney International, vol. 67, no. 5, pp. 1934–1943, 2005.
[12]
M. Daudona and P. Jungers, “Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi,” Nephron Physiology, vol. 98, no. 2, pp. p31–p36, 2004.
[13]
Z.-J. Huang, J.-J. Li, J.-Y. He, and J.-M. Ouyang, “Study on nano- and microcrystallites in the urines of calcium oxalate stone formers,” Spectroscopy and Spectral Analysis, vol. 30, no. 7, pp. 1913–1917, 2010.
[14]
M.-X. Zhao, X.-J. Xu, and J.-M. Ouyang, “Comparative research on nanocrystals and crystallites in urines of healthy persons and stone patients,” Journal of Jinan University Natural Science and Medicine Edition, vol. 28, no. 5, pp. 486–490, 2007.
[15]
Y.-F. Shang, L. Kuan, W.-Y. Zhu, and J.-M. Ouyang, “Washing method, an accurate detection method of urinary nanocrystallites to eliminate interference of soluble components in urine,” Advanced Materials Research, vol. 781–784, pp. 932–935, 2013.
[16]
S. J. Peng and S. F. Ding, “Determination of citric acid by activation catalytic reaction system of potassium bromate-bromophenol blue-vanadium (V) dynamic spectrophotometric,” Chinese Journal of Health Laboratory Technology, vol. 21, no. 8, pp. 1845–1846, 2011.
[17]
P. Whiteman, “The quantitative determination of glycosaminoglycans in urine with Alcian Blue 8GX,” Biochemical Journal, vol. 131, no. 2, pp. 351–357, 1973.
[18]
M. King, W. F. McClure, and L. C. Andrews, Powder Diffraction File Alphabetic Index, Inorganic Phases/Organic Phases, International Center for Diffraction Data, Newtown Square, Pa, USA, 1992.
[19]
A. Trinchieri, C. Castelnuovo, R. Lizzano, and G. Zanetti, “Calcium stone disease: a multiform reality,” Urological Research, vol. 33, no. 3, pp. 194–198, 2005.
[20]
S. Srinivasan, P. Kalaiselvi, R. Sakthivel, V. Pragasam, V. Muthu, and P. Varalakshmi, “Uric acid: an abettor or protector in calcium oxalate urolithiasis? Biochemical study in stone formers,” Clinica Chimica Acta, vol. 353, no. 1-2, pp. 45–51, 2005.
[21]
X.-A. Gu, X.-Y. Li, and C.-T. Sun, “Potassium citrate prevents calcium oxalate stone formation in clinical research,” Chinese Medical Journal, vol. 36, no. 8, pp. 22–23, 2001.
[22]
D. J. Kok, “Clinical implications of physicochemistry of stone formation,” Endocrinology and Metabolism Clinics of North America, vol. 31, no. 4, pp. 855–867, 2002.
[23]
Y.-S. Ha, D.-U. Tchey, H. W. Kang et al., “Phosphaturia as a promising predictor of recurrent stone formation in patients with urolithiasis,” Korean Journal of Urology, vol. 51, no. 1, pp. 54–59, 2010.
[24]
J. A. Dean and H. McGraw, “Citric acid,” in Lange's Handbook of Chemistry, pp. 5–46, McGraw-Hill, 13th edition, 1985.
[25]
H. A. Fuselier and D. M. Ward, “Urinary Tamm-Horsfall protein increased after potassium citrate therapy in calcium stone formers,” Urology, vol. 45, no. 6, pp. 942–946, 1995.
[26]
D. J. Kok, Inhibitors of Crystallization. I. Calcium Oxalate in Biological Systems, CRC Press, 1995.
[27]
M. L. Weaver, S. R. Qiu, J. R. Hoyer, W. H. Casey, G. H. Nancollas, and J. J. de Yoreo, “Inhibition of calcium oxalate monohydrate growth by citrate and the effect of the background electrolyte,” Journal of Crystal Growth, vol. 306, no. 1, pp. 135–145, 2007.
[28]
S. Guo, M. D. Ward, and J. A. Wesson, “Direct visualization of calcium oxalate monohydrate crystallization and dissolution with atomic force microscopy and the role of polymeric additives,” Langmuir, vol. 18, no. 11, pp. 4284–4291, 2002.
[29]
V. Fischer, K. Landfester, and R. Mu?oz-Espí, “Stabilization of calcium oxalate metastable phases by oligo(L-glutamic acid): effect of peptide chain length,” Crystal Growth and Design, vol. 11, no. 5, pp. 1880–1890, 2011.
[30]
A. Wierzbicki, C. S. Sikes, J. D. Sallis, J. D. Madura, E. D. Stevens, and K. L. Martin, “Scanning electron microscopy and molecular modeling of inhibition of calcium oxalate monohydrate crystal growth by citrate and phosphocitrate,” Calcified Tissue International, vol. 56, no. 4, pp. 297–304, 1995.
[31]
J. M. Ouyang, X. Q. Yao, Z. X. Su, and F. Z. Cui, “Simulation of calcium oxalate stone in vitro,” Science in China B, vol. 46, no. 3, pp. 234–242, 2003.